CAVE CREEK, AZ, March 21, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE –CBD Unlimited, Inc. (EDXC) formerly known as Endexx Corporation, a provider of innovative phytonutrient-based food and nutritional products, is pleased to announce the introduction of its Premium Blue Line CBD. The Premium Blue Line was introduced to retail buyers at the ECRM Hemp/CBD Health & Beauty Care conference 2019.
CBD Unlimited’s “Premium Blue Line X” represent the company’s “Controlled-Dosing, Targeted-Delivery and Dual Therapy” product suite. The products have proven to generate the best customer experience and is fully scalable for mass market product and delivery. During the pilot program the suite generated the greatest adoption and reorder rate across all distribution points of sale throughout the United states from 2016-2018.
“We are thrilled to expand our product line to include our new Premium Blue Line X,” commented CEO & Chairman Todd Davis. “We are always innovating and looking for new ways to enhance our family of products. Ultimately, the consumer fuels our innovation. We look at what the consumer calls for and formulate accordingly.”
About CBD Unlimited, Inc.
CBD Unlimited, Inc., with its collaborative partners and consultants, develops and distributes two consumable product lines derived from Hemp, which is all-natural and rich in phyto-cannabinoids. CBD Unlimited provides only the highest quality M3CBD® hemp based nutritional extracts that are rich in non-psychoactive phyto-cannabinoids and terpenoids, and are formulated to the highest standard of purity and “Serving or MG”(milligram) accuracy. Phyto-Bites® is its CBD-infused soft chews for dogs. The dog treats are formulated to promote health and support the reduction of separation anxiety, pain and inflammation.
The company also has two key technology products and services that launched in 2014. Both products provide essential solutions to promote regulatory compliance and full accountability through asset protection, inventory management, compliance and an “end of sale” technology integration. Based on principles developed by the pharmacological industry, the integrated “Gorilla-Tek” platform is the first standardized hardware agnostic and software solution for tracking high- risk high-shrink regulated and restricted products that maintains compliance with federal, state and local regulations. It is intended to provide conformity with federal and state mandates. Gorilla-Tek™ is also a commercial-grade inventory control and dispensing device that provides up-to-the-minute accounting details and ensures both product and patient security. By automating the dispensing process, Gorilla-Tek™ increases productivity and reduces costs for retailers, while enhancing their service quality by reducing transaction time for customers.
ECRM helps buyers and suppliers increase productivity, optimize product assortments and enhance collaboration efforts via its service offerings that include product discovery, category development and category planning.
Safe Harbor Notice
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future development activities and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the company’s business and finances in general, including the ability to continue and manage its growth, competition, global economic conditions and other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The company undertakes no obligation to update any forward-looking statements.
For further investor and media information, please contact:
CBD Unlimited, Inc.
Chairman & CEO